What Does MyoKardia Do?

Total employees33
HeadquartersBrisbane
Founded2012

MyoKardia was a clinical-stage biopharmaceutical company dedicated to pioneering a precision medicine approach for treating serious and often neglected cardiovascular diseases. Founded in 2012, MyoKardia's core mission was to develop targeted therapies that address the underlying genetic and biochemical drivers of conditions such as hypertrophic cardiomyopathy (HCM). Their lead therapeutic candidate, mavacamten (marketed as Camzyos®), is a first-in-class allosteric modulator of cardiac myosin, specifically designed to reduce the excessive heart muscle contraction characteristic of HCM. In a landmark move for its cardiovascular franchise, Bristol Myers Squibb (BMS) acquired MyoKardia in November 2020 for $13.1 billion, integrating MyoKardia's innovative pipeline, including mavacamten, and specialized expertise into BMS.

Where Is MyoKardia's Headquarters?

HQ Function

Served as the primary center for MyoKardia's research and development activities, clinical operations, and corporate administration, focusing on the discovery and advancement of targeted cardiovascular therapies.

Notable Features:

The headquarters was likely located within a modern life sciences campus, equipped with specialized laboratory facilities necessary for biopharmaceutical research and drug development, alongside collaborative office environments.

Work Culture:

MyoKardia's work culture was characterized by a strong emphasis on scientific innovation, a patient-first approach to drug development, and a dynamic, fast-paced environment typical of a pioneering biotechnology firm. Collaboration and scientific excellence were key tenets.

HQ Significance:

This headquarters was the birthplace of significant advancements in cardiology, most notably the development of mavacamten, a transformative treatment for hypertrophic cardiomyopathy. It symbolized the company's leadership in precision medicine for heart conditions.

Values Reflected in HQ: The headquarters embodied MyoKardia's core values of scientific rigor, dedication to patient needs, and the pursuit of groundbreaking therapies for underserved cardiovascular diseases.

Location:

Before being acquired by Bristol Myers Squibb, MyoKardia's direct operational footprint was largely concentrated in the United States, centered on its research, clinical development, and corporate activities. While its R&D and corporate base was in California, its clinical trials for promising drug candidates like mavacamten involved investigative sites across North America, Europe, and other regions to ensure comprehensive and diverse patient data. Since the acquisition, MyoKardia's innovations, especially its flagship product Camzyos (mavacamten), are being developed, manufactured, and commercialized on a global scale through Bristol Myers Squibb's extensive worldwide infrastructure, making these therapies accessible to patients in numerous countries.

Street Address:

1000 Sierra Point Parkway

City:

Brisbane

State/Province:

California

Country:

USA

Where Else Does MyoKardia Operate Around the World?

N/A - Operations Centralized

Address: N/A

MyoKardia's strategy involved focusing its primary operational infrastructure and talent at a single main site to foster close collaboration and efficiency in its drug development efforts.

Buying Intent Signals for MyoKardia

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Who's Leading MyoKardia? Meet the Executive Team

As of April 2025, MyoKardia' leadership includes:

Tassos Gianakakos - President and Chief Executive Officer (Pre-Acquisition)
Taylor C. Harris - Chief Financial Officer (Pre-Acquisition)
Robert S. McDowell, Ph.D. - Chief Scientific Officer (Pre-Acquisition)
William C. Fairey - Chief Commercial Officer (Pre-Acquisition)
Jake Bauer - Chief Business Officer (Pre-Acquisition)
Cynthia Bodison - General Counsel and Corporate Secretary (Pre-Acquisition)

Who's Investing in MyoKardia?

MyoKardia has been backed by several prominent investors over the years, including:

Third Rock Ventures (Founding Investor)
Fidelity Management & Research Company
RA Capital Management
Perceptive Advisors
Casdin Capital
Wellington Management Company

What Leadership Changes Has MyoKardia Seen Recently?

Hire0
Exits0

Following the acquisition by Bristol Myers Squibb in November 2020, MyoKardia ceased to operate as an independent public company. Its executive team members largely transitioned to roles within Bristol Myers Squibb, pursued new opportunities, or departed after assisting with the integration. Consequently, specific 'MyoKardia' executive hires or exits in the last 12-24 months are not applicable as it is no longer a standalone entity. The most significant executive 'news' was the acquisition itself and the subsequent changes in leadership structure as MyoKardia's assets and personnel were integrated into BMS.

What Technology (Tech Stack) Is Used byMyoKardia?

Discover the tools MyoKardia uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

MyoKardia Email Formats and Examples

Prior to its acquisition by Bristol Myers Squibb, MyoKardia, Inc. likely utilized standard corporate email formats common in the biopharmaceutical industry. These email formats are no longer in active use for MyoKardia as an independent entity, as communications are now handled through Bristol Myers Squibb channels. Common historical patterns included combinations of first name, last name, and initial.

Likely formats included [first_initial][last]@myokardia.com (e.g., jdoe@myokardia.com) or [first].[last]@myokardia.com (e.g., jane.doe@myokardia.com).

Format

example@myokardia.com

Example

0 (domain is no longer independently active; emails would not be delivered)%

Success rate

What's the Latest News About MyoKardia?

Bristol Myers SquibbNovember 17, 2020

Bristol Myers Squibb Completes Acquisition of MyoKardia

Bristol Myers Squibb announced the successful completion of its acquisition of MyoKardia for $13.1 billion. This strategic acquisition significantly enhances BMS's cardiovascular portfolio with the addition of mavacamten, a potential first-in-class medicine for obstructive hypertrophic cardiomyopathy....more

Bristol Myers SquibbApril 28, 2022

MyoKardia's Pioneered Drug, CAMZYOS™ (mavacamten), Approved by FDA under BMS

The U.S. Food and Drug Administration (FDA) approved CAMZYOS™ (mavacamten), a therapy originally developed by MyoKardia, for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM). This approval marked a major success for the science MyoKardia advanced....more

MyoKardia / BMSOctober 5, 2020

MyoKardia Agrees to be Acquired by Bristol Myers Squibb

MyoKardia announced it had entered into a definitive agreement to be acquired by Bristol Myers Squibb for $225.00 per share in cash, an aggregate value of $13.1 billion. The deal was aimed at leveraging BMS's resources to maximize the potential of mavacamten and MyoKardia's pipeline....more

MyoKardia (Archived News)May 29, 2019

MyoKardia Announces Positive Top-Line Results from Pivotal Phase 3 EXPLORER-HCM Study of Mavacamten

MyoKardia reported positive top-line results from its pivotal Phase 3 EXPLORER-HCM clinical trial evaluating mavacamten in patients with obstructive hypertrophic cardiomyopathy. The study met its primary endpoint, demonstrating statistically significant and clinically meaningful improvements in symptoms and cardiac function....more

Highperformr's free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including MyoKardia, are just a search away.